VivoSeq
Other

Antibody Response

0

Pipeline Programs↗

1

Active Trials↗

5

Companies Involved↗

Antibody Response is an early-stage landscape with 0 programs across 5 companies. The most active players are Novartis, GSK, Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalMerck & Co. logo

Merck & Co.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

20

clinical trials

Completed15 · 75%
Unknown status2 · 10%
Terminated2 · 10%
Active, not recruiting1 · 5%

Clinical Trials

Trial Activity

20 trials

Assessing Durable Antibody Response to HPV Vaccination
Active, not recruiting·EEmory University·Phase 4·NCT05031078·17 enrolled
Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients
Completed·Novartis logoNovartis·Phase 2·NCT01097096·177 enrolled
Treatment of Deficient Subclass or Anti-polysaccharide Antibody Response
Completed·PProthya Biosolutions·Phase 4·NCT00522821·55 enrolled
The Aim of This Study is to Investigate the Persistence of Antibody Response in Adults up to 15 Years After One Booster Dose of GlaxoSmithKline (GSK) Biologicals' Encepur Adults Vaccine
Completed·GSK logoGSK·Phase 4·NCT03294135·194 enrolled
BioRBC Survival in Adults With Prior Antibody Response to BioRBCs
Completed·—·Phase 1·NCT02077751·3 enrolled
Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine
Completed·Novartis logoNovartis·Phase 3·NCT01345721·205 enrolled
Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys
Completed·KKenya Medical Research Institute·N/A·NCT04711265·176 enrolled
Long-term Immunogenicity After Receipt of JE Vaccine and Antibody Response and Safety to a Booster Dose
Completed·PPATH·Phase 4·NCT02514746·561 enrolled
Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose.
Completed·Pfizer logoPfizer·Phase 3·NCT01026038·263 enrolled
The Safety and Antibody Response of the Nasal COV2 Vaccine Against the SARS-CoV-2 Virus
Completed·RRokote Laboratories Finland Oy·Phase 1·NCT06851611·40 enrolled
Polysaccharide Antibody Response Study
Completed·UUniversitaire Ziekenhuizen KU Leuven·Phase 4·NCT02429531·200 enrolled
Persistence of Antibody Response to N. Meningitidis Group C in Children
Completed·Novartis logoNovartis·Phase 4·NCT00316654·489 enrolled
Babies Born Early Antibody Response to Men B Vaccination: BEAR Men B
Completed·SSt George's, University of London·Phase 4·NCT03125616·136 enrolled
Seroprevalence of Bordetella Pertussis Antibodies and Anti-pertussis Antibody Response After a Single Dose of Tdap in Pregnant Thai Women
Completed·MMahidol University·Phase 1·NCT03498300·129 enrolled
Investigating Immunisation Strategies of DNA, MVA and CN54rgp140 Adjuvanted With GLA-AF to Maximise Antibody Responses
Completed·IImperial College London·Phase 1·NCT01922284·40 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)